Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.

Cancer research - 1 Mar 2009

Sartore-Bianchi Andrea, Martini Miriam, Molinari Francesca, Veronese Silvio, Nichelatti Michele, Artale Salvatore, Di Nicolantonio Federica, Saletti Piercarlo, De Dosso Sara, Mazzucchelli Luca, Frattini Milo, Siena Salvatore, Bardelli Alberto

Abstract excerpt

The monoclonal antibodies (moAb) panitumumab and cetuximab target the epidermal growth factor receptor (EGFR) and have proven valuable for the treatment of metastatic colorectal cancer (mCRC). EGFR-mediated signaling involves two main intracellular cascades: on one side KRAS activates BRAF, which in turn triggers the mitogen-activated protein kinases. On the other, membrane localization of the lipid kinase PIK3CA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Class I Phosphatidylinositol 3-Kinases

Share to Genes, ras

Share to Panitumumab

Share to Phosphatidylinositol 3-Kinases

Share to PTEN Phosphohydrolase

Source

Identifiers

PMID: 19223544
DOI: 10.1158/0008-5472.CAN-08-2466

Genes

KRAS
EGFR
PTEN
AKT1
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.PMID 19223544Read ↗

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.Semantic proximity Read ↗

PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.Semantic proximity Read ↗

The dark side of the moon: the PI3K/PTEN/AKT pathway in colorectal carcinoma.Semantic proximity Read ↗

The Landscape of PIK3CA Mutations in Colorectal Cancer.Semantic proximity Read ↗

The role of PIK3CA gene mutations in colorectal cancer and the selection of treatment strategiesSemantic proximity Read ↗

Prognostic and Predictive Value of PIK3CA Mutations in Metastatic Colorectal Cancer.Semantic proximity Read ↗

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer.Semantic proximity Read ↗

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.Semantic proximity Read ↗

PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis.Semantic proximity Read ↗

Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone.Semantic proximity Read ↗

Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS.Semantic proximity Read ↗

PIK3CA mutation is predictive of poor survival in patients with colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.